摘要
1型糖尿病以胰岛素绝对缺乏为特征。外源性胰岛素替代治疗是1型糖尿病的重要治疗方式,但其非生理性的胰岛素输注方式会导致医源性高胰岛素血症,加重外周胰岛素抵抗,进而增加各类并发症的风险。新型胰岛素输注技术、生活方式干预以及二甲双胍等药物也逐步应用于1型糖尿病患者以降低血浆胰岛素水平,进而改善患者的预后。
Type 1 diabetes is characterized by an absolute deficiency of insulin.Exogenous insulin replacement therapy is a crucial treatment approach for type 1 diabetes.However,the non-physiological insulin administration can lead to iatrogenic hyperinsulinemia,exacerbate peripheral insulin resistance,and subsequently increase the risk of various complications.Emerging insulin infusion technologies,lifestyle interventions,and medications such as metformin are increasingly being utilized in type 1 diabetes management to lower plasma insulin levels and improve patient outcomes.
作者
李爽
刘静飞
陈阳
顾愹
杨涛
Li Shuang;Liu Jingfei;Chen Yang;Gu Yong;Yang Tao(Department of Endocrinology and Metabolism,First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2024年第9期811-816,共6页
Chinese Journal of Endocrinology and Metabolism
基金
国家自然科学基金(81900708)。
关键词
糖尿病
1型
医源性高胰岛素血症
胰岛素抵抗
Diabetes mellitus,type 1
Iatrogenic hyperinsulinemia
Insulin resistance
